TACR3 and central nervous system disorder: Finally, as a major representative of the NK3 antagonist family, and as a compound examined in clinical trials for treatment of CNS disorders, Talnetant exhibited high affinity for human NK3 and long-lasting in vivo activity, justifying its selection as a starting scaffold for non-peptidic NK3 ligand design [27].